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Abstract 
Quantitative ffects of inhibitors of the replicative IX&IA polyrnerases (pol) a, Sand E from calf thymus are reported under similar assay conditions. 
Carbonyldiphosphonate was a competitive inhibitor of pols S and E, with 4- to &fold selectivity compared to pol a. Aphidicolin inhibited pols u 
and 6 with 6- to IO-fold selectivity compared to pol E. The ‘butylphenyl’ nucleotides, BuPdGTP and BuAdATP, inhibited pol Q with at least lOOO-fold 
selectivity compared to pols 6 and E. The use of these inhibitors under similar assay conditions permits the discrimination of the three enzymes. 
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1. Introduction 
The suggestion that multiple DNA polymerases (pol) 
catalyze eukaryotic DNA replication (reviewed in El]) 
has been supported by the use of selective inhibitors. 
Monoclonal antibodies and selective small molecule in- 
hibitors of DNA polymerase CI revealed a novel enzyme, 
designated DNA polymerase 6, that could be separated 
from DNA polymerase CI, but that contained an intrinsic 
3’ to 5’ exonuclease activity [2,3]. Among the properties 
of this enzyme, its activity on homopol~er templates 
was found to be stimulated by proliferating cell nuclear 
antigen (PCNA), supporting a role for the enzyme in 
nuclear DNA replication [4,5]. However, 3’ to 5’ exonu- 
clease-containing pols insensitive to PCNA were isolated 
from several sources (summarized in [6]), and genetic and 
sequencing studies have revealed this to be a third en- 
zyme, designated pol E [7], also proposed to be involved 
in DNA replication and, possibly, repair (reviewed in 
IW. 
The ability to identify isolated DNA polymerases and 
their role(s) in DNA replication in whole cells, nuclei or 
nuclear preparations requires, among other properties, 
careful definition of the inhibitor sensitivities of the en- 
zymes. The diterpene aphidicolin has been reported to 
inhibit pols CZ, 6 and E with similar potencies [9]. The 
synthetic nucleotides BuPdGTP and BuAdATP {the ‘bu- 
tylphenyl’ nucleotides), however, are highly selective for 
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inhibition of pol 01 compared to their effects on pols S 
and E ([9], reviewed in [lo]). In a search for a selective 
inhibitor of pol S, at a time when pol E was still unrecog- 
nized, we first identified a pyrophosphate analog, dif- 
luoromethylene-diphosphonate, as a weak but selective 
inhibitor of calf thymus ~016 [l I]. That discovery led to 
the finding that a related compound, carbon- 
yldiphosphonate (COMDP), was a potent inhibitor of 
pol S, with about tenfold selectivity relative to its effect 
on calf thymus pol a [12]. However, the enzyme prepara- 
tion used to identify COMDP was a PCNA-insensitive 
form of ~016 [ 131, an enzyme now properly identified as 
pol E [6]. Although there have been several reports in 
which COMDP has been suggested to inhibit ~016 selec- 
tively, no systematic study of the relative potencies of this 
and the other small molecule inhibitors for the three 
enzymes has been reported. Given that all three enzymes 
have been isolated from calf thymus [6], we now report 
a direct comparison of in~bitor sensiti~ties of pols cc, 6 
and E from that tissue, and suggest limitations in the use 
of inhibitors to distinguish the enzymes. 
2. Materials and methods 
Aphidicolin was a gift from the Natural Products Chemistry Branch, 
national cancer institute. Other inhibitors were synthesti as de- 
scribed: carbonyldiphosphonate (COMDP), tetrasodium salt, accord- 
ing to [12], p-(p-n-butylphenyl)-2’-de oxyguanosine 5’-triphosphate 
(BuPdGTP) according to [14], and 2-@-n-butylanilino)-2’-deoxyad- 
enosine 5’-triphosphate (BuAdATP) according to [15]. Calf thymus pol 
a was purified on an immunoaffinity matrix as described [ 161. Calf 
thymus pol e was the FPLC-purified fraction [13], and pol 6 was 
separated from pol E on hydroxyapatite [6]. PCNA was purified accord- 
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ing to [17]. Nucleotides and oligonucleotides were from Pharmacia, and 
all chemicals were reagent grade. 
Enzymes were assayed in 25 ~1 reaction volumes containing 75 mM 
HEPES KOH (pH 7.5), 20% glycerol, 1.25 mM dithiothreitol, 10 mM 
MgCl,, 250 pug/I;;1 bovine se& albumin, 0.1 mM poly dA: oligo dT 
(base ratio 10: 1) and 5 uM I’HldTTP (1250 cmn/nmol). One mM GMP 
I ,.A 
was present in assays of ~016 and pol E to &h&it 3’ to 5’ exonuclease 
activity. PCNA (50 ng) was present in each pol S assay. Reactions were 
initiated by the addition of enzyme: 0.1 unit of pol a, 0.08 unit of pol 
6, or 0.05 unit of pol E. The reactions were incubated for 30 min (pol 
a) or 60 min (pol S, pol E) at 37”C, and stopped by addition of 10 mM 
EDTA and 2 pg of heat- denatured DNA. Polynucleotides were precip- 
itated by the addition of 1 ml of 10% trichloroacetic acid, filtered 
through GFA circles (Whatman), and washed with 10 ml of 1 N HCl 
containing 100 mM sodium pyrophosphate, and finally with ethanol. 
Dried filters were counted in 1 ml of Optilluor. Control activities corre- 
sponded to 28.4, 12 and 20.8 pmol dTMP incorporated per assay tube 
for pols a, 6 and E, respectively. 
Inhibitors were tested by addition of stock solutions in water 
(BuPdGTP, BuAdATP), HEPESKOH buffer (COMDP), or dimeth- 
ylsulfoxide (aphidicolin); control assays contained the same volume of 
inhibitor diluent. The percent inhibition of enzyme activity at 65 con- 
centrations of inhibitor was plotted as a function of log concentration 
to obtain the I& values. Results from duplicate experiments were in 
the range of f 30%. Ki values for COMDP are the average of Ki = 
I/[(K,,,‘l K,)-11, where 6 is the apparent K, of dTTP in the presence 
of COMDP at concentration I. K,,, values were obtained with the com- 
puter program Enzyme Kinetics (D.G. Gilbert, Indiana University). 
3. Results and discussion 
In order to compare inhibitor sensitivities under simi- 
lar assay conditions, all enzymes were assayed by incor- 
poration of [3H]dTTP into poly dA: oligo dT (base ratio 
10 : 1). This template: primer is one of only few that sus- 
tain activity of all three enzymes, although pol 6 is only 
active in this system in the presence of PCNA [6]. A 
template : primer suitable for mechanistic stud- 
ies of BuPdGTP, i.e. poly dC : oligo dG, poorly sustained 
pol 6 activity even in the presence of PCNA (data not 
shown). To assure the identity of DNA polymerases 6 
and E the response of each to PCNA was tested first. The 
results of Fig. 1 show that the activity of pol 6 was 
stimulated fifteenfold by 200 ng PCNA/assay, but pol E 
was unaffected. Thus, in all subsequent experiments inhi- 
bition of ~016 was tested in the presence of 50 ng PCNA/ 
assay. 
Typical percent inhibition/log concentration curves 
for the three enzymes are displayed in Fig. 2, and the I&, 
values are summarized in Table 1. The enzymes were 
assayed in HEPES buffer because COMDP is inac- 
tivated in the customary Tris buffer [12]. COMDP inhib- 
ited ~016 and pol E with similar potencies, demonstrating 
that the compound is an equivalent inhibitor of both 
enzymes. However, COMDP had only 4- to 6-fold selec- 
tivity for these enzymes relative to its effect on pol a (Fig. 
2B), compared to the tenfold selectivity previously re- 
ported for pol E [12]. This result may be due, in part, to 
the different mechanisms of inhibition of the enzymes. 
COMDP was found to be a non-competitive inhibitor of 
pol a, but a competitive inhibitor of pol E [ 121. Indeed, 
0 50 100 150 200 250 
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Fig. 1. Effect of PCNA on calf thymus pols S and E. Enzymes were 
assayed with poly dA : oligo dT (10 : 1) and 5 PM [‘H]dTTP as described 
in section 2. 
analysis of the inhibitory effect of COMDP in assays 
with poly dA:oligo dT at several dTTP concentrations 
revealed competitive kinetics for both pol 6 and pol E 
(data not shown). For ~016 the Ki was 4.0 PM, and the 
K, for dTTP was 3.1 ,uM. For p01 E the Ki was 4.9 PM, 
and the K,,, for dTTP was 5.7 ,uM. The latter result 
contrasts with the competitive Ki value of 1.8 PM previ- 
ously reported for inhibition of pol E in the same assay 
system [12]. 
The nucleotides BuPdGTP (Fig. 2A) and BuAdATP 
clearly inhibited pol a selectively, with IC,, values at 
least three orders of magnitude lower than those for pol 
6 and pol E (Table 1). The typical nanomolar inhibitory 
potency of the nucleotides against pol a was not ob- 
served, because the assay involved a template, poly dA, 
which is not complementary to the base of either com- 
pound [18]. However, the sub-micromolar potencies ob- 
served are consistent with the template-independent, 
non-substrate mechanism by which these butylphenyl 
nucleotides inhibit pol a in this assay system [16]. 
Aphidicolin inhibited both pol a and ~016 with similar 
potencies, but was a weaker inhibitor of pol E (Table 1; 
Table 1 
Inhibitors of calf thymus DNA polymerases’ 
Inhibitor IC,, ‘&M) 
pol a pol a2 PO1 E 
COMDP 26.2 4.4 6.7 
Aphidicolin 0.5 0.9 5.8 
BuPdGTP 0.026 100 87 
BuAdATP 0.18 138 184 
’ Enzymes were assayed with poly dA: oligo dT (10: 1) and 5 PM 
[‘H]dTTP as described in section 2. 
’ + 50 ng PCNA per assay. 
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Fig. 2. Percent inhibition/log inhibitor concentration curves for calf thymus pol inhibitors: BuPdGTP (panel A), COMDP (panel B) and aphidicolin 
(panel C). Inhibitor assays were done as described in section 2. 0, pol a; l , pol 6; v, pol E. 
Fig. 2B). Aphidicolin has been reported to inhibit pol a 
competitively with each dNTP [19]. Thus, the relative 
potencies in Table 1 suggest hat aphidicolin can distin- 
guish pol E from both pol CI and pol S under these assay 
conditions. 
In summary, pols CI, 6 and E may be distinguished by 
selective inhibitors when assayed under similar assay 
conditions. Pol 01 can clearly be distinguished from pols 
6 and E, first by the much greater sensitivity of the former 
enzyme to BuPdGTP and BuAdATP, and second by the 
marginally greater sensitivity of the latter enzymes to 
COMDP. The results of this work suggest hat pol E may 
be distinguished from pol 6 (and pol a) by the lesser 
sensitivity of pol E to aphidicolin. 
The I&, results for COMDP and aphidicolin (Table) 
are consistent with reported effects of single concentra- 
tions of the inhibitors on the calf thymus [6] and HeLa 
[20] DNA polymerases. However, the marginal selectiv- 
ity of both COMDP and aphidicolin for the respective 
enzymes indicates that inhibition results may only be 
reliable at concentrations that partially inhibit the more 
sensitive enzyme. The inhibition curves in Fig. 2B show 
that 5 ,uM COMDP will inhibit both ~016 and pol E by 
-5O%, but pol a will be almost unaffected. Similarly, 
aphidicolin at 1 PM will inhibit both pol a and pol 6 by 
>50%, but pol E will be almost unaffected (Fig. 2C). The 
most selective inhibitors, BuPdGTP (Fig. 2A) and 
BuAdATP, at l-lOpM, will completely inhibit pol CI, but 
pol 6 and pol E will be unaffected. The limitations in 
ability to distinguish pol 6 and pol E stimulate our con- 
tinued search for selective inhibitors of these enzymes. 
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